Featured science studies simultaneously published in JACC and presented at AHA 2025 looked at artificial intelligence applied to an electrocardiogram (ECG-AI) for heart failure (HF) risk, treatment of Chagas disease, early aspirin withdrawal in STEMI and non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and safety of the pentaspline pulsed-field ablation (PFA) catheter.
JACC Featured Science: ECG-AI For HF Risk; ANSWER-HF; NEO-MINDSET; MANIFEST-US
Related Articles
Mayo Clinic launches remote diagnostics platform, forms 2 new companies to support it
Healthcare IT News: Anumana will develop and market algorithms for early detection of disease. Lucem Health can collect device data and feed it into clinical workflows. Both spin-offs aim to…April 13, 2021
Pfizer and Anumana boost detection of cardiovascular disease
Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.December 16, 2022
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.October 02, 2023
Philips Launches ECG-AI Marketplace to Enhance Early Cardiac Diagnosis
Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystemJuly 17, 2025